Intellia Therapeutics is set to report topline data from its global phase 3 HAELO clinical trial of lonvoguran ziclumeran for hereditary angioedema. Some reports indicate positive phase 3 results have already been achieved, marking a potential milestone for in vivo gene editing, while others suggest additional data will be presented. The status of the trial's outcome remains somewhat unclear, with various updates and presentations scheduled or already having taken place.